Wie hoch ist der Preis für ProMIS Neurosciences, Inc. (PMN)

Preis für ProMIS Neurosciences, Inc. (PMN) ist $4.40

Wie hoch ist die Marktkapitalisierung für ProMIS Neurosciences, Inc. (PMN)

Marktkapitalisierung für ProMIS Neurosciences, Inc. (PMN) ist $37.78M

ProMIS Neurosciences, Inc. (PMN) KBV

Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Moderna, Inc. MRNA.US	3.7087	-	US
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land